Radiomer Therapeutics, a Houston, TX-based Fannin Companions-founded firm that’s creating focused radiopharmaceuticals / radioligand therapies for theranostic purposes, has been launched with undisclosed pre-seed funding.
The corporate intends to make use of the funds to proceed improvement of its radiopharmaceutical/ radioligand remedy platform and applications.
Led by Atul Varadhachary, MD, PhD, CEO, and Phil Breitfeld, MD, Chief Medical Officer, Radiomer leverages Fannin’s proprietary RaptamerTM platform as concentrating on vectors/ligands for theranostic utility. A Raptamer is a novel concentrating on agent that consists of a single-stranded (ss) DNA spine adorned with peptide-like aspect chains so as to add chemical variety and enhance binding affinity. The modular Raptamer construction permits the addition of a wide range of linkers, chelators and isotope payloads.
Radiomer has a wealthy pipeline of belongings in improvement with lead applications anticipated to finish Part 0 imaging/dosimetry trial(s) in most cancers sufferers in Q1 2025. Lead applications tackle main cancers together with breast, lung, colorectal, prostate, and head and neck cancers.
Created in 2023, Radiomer Therapeutics operated in stealth throughout the previous 12 months, producing knowledge utilizing the rights to radiopharmaceutical purposes for Fannin’s Raptamer concentrating on platform, which has been within the portfolio since 2019.
Established in 2014, Houston-based Fannin is among the many most energetic early-stage product improvement teams within the life sciences with a dozen applications/ platforms at completely different phases of improvement. Fannin advances its pipeline each internally and thru Fannin-founded entities with a mix of investor and grant funding. Within the final decade, Fannin has introduced in ~35 applications, of which a dozen are energetic together with three within the clinic. Collectively, ~$242m has been invested throughout Fannin applications, $71M from grant funding and $171M from buyers.
FinSMEs
30/05/2024
